Coronavirus (COVID-19) News
Filter News
Found 2,615 articles
-
bioLytical Laboratories Inc. receives WHO PQ for its iStatis COVID-19 Antigen Home Test
10/18/2022
bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced it has received its WHO PQ for its self-test, the iStatis COVID-19 Antigen Home Test, allowing its immediate entry into international markets.
-
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
10/17/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022.
-
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
10/14/2022
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.
-
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
10/14/2022
MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.
-
Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.
-
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
10/13/2022
Pfizer Inc. and BioNTech SE announced early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
-
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
10/12/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age.
-
March of Dimes Releases Third Maternity Care Deserts Report Revealing Access to Care is Getting Worse During Covid-19
10/11/2022
March of Dimes released its 2022 report, Nowhere to Go: Maternity Care Deserts Across the U.S., revealing access to maternity care is diminishing in places where it's needed most, impacting nearly seven million American women of childbearing age and roughly 500,000 babies.
-
ScreenPro Provides COVID-19 Testing Updates
10/11/2022
ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that the Company is currently providing Covid-19 testing to eleven (11) film and production companies in Canada.
-
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
10/10/2022
Ascletis Pharma Inc. announces dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent RNA polymerase inhibitor ASC10 for COVID-19 at the National Medical Center for Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University.
-
Largest study measuring extent of COVID-19 in Canadian children and teens now underway
10/6/2022
In Canada, the vast majority of COVID-19 cases in the 0 to 18 age group have been mild or asymptomatic. This fact, combined with the reduction in routine COVID-19 laboratory testing across most of the country, means that the infection rates in children and adolescents are largely unknown.
-
Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response
10/4/2022
Elicio Therapeutics announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology, demonstrating Elicio’s Amphiphile platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization.
-
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
10/4/2022
Dyadic International, Inc. announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Barcelona, Spain.
-
Sense and Abacus dx Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in Australia and New Zealand
10/4/2022
Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with Abacus dx for the non-exclusive distribution in Australia and New Zealand of Sense’s Veros instrument-free, point-of-care molecular testing platform.
-
PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
10/4/2022
PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed cGMP manufacturing of a multi-kilogram lot of cepharanthine-2HCl for use in the final drug product production of PD-001, its patented, orally bioavailable version of cepharanthine.
-
Adamis Announces Review of Strategic Alternatives
10/3/2022
Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.
-
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
10/3/2022
RedHill Biopharma Ltd. announced study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 1 and twice-daily opaganib2.
-
Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine
9/29/2022
Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, and Centre National de Recherche et de Formation sur le Paludisme, the Burkina Faso site team lead by Dr. Gansane Adama, announced that enrollment is now complete into the single and two-dose cohorts of the Phase 2 clinical trial of Covigenix VAX-001-1b, its COVID-19 DNA vaccine.
-
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
9/28/2022
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases
-
Pediatric and Autonomic Dysfunction Long COVID Symptoms Guidance Statements Released by the American Academy of Physical Medicine and Rehabilitation
9/28/2022
The American Academy of Physical Medicine and Rehabilitation announced new guidance for diagnosing and treating pediatric patients with Long COVID symptoms and patients with autonomic dysfunction symptoms of Long COVID.